86 related articles for article (PubMed ID: 16059651)
1. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.
Boudny V; Dusek L; Adámková L; Chumchalová J; Kocak I; Fait V; Lauerová L; Krejcí E; Kovarík J
Neoplasma; 2005; 52(4):330-7. PubMed ID: 16059651
[TBL] [Abstract][Full Text] [Related]
2. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation.
Kovarik J; Boudny V; Kocak I; Lauerova L; Fait V; Vagundova M
Int J Mol Med; 2003 Sep; 12(3):335-40. PubMed ID: 12883649
[TBL] [Abstract][Full Text] [Related]
3. Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients.
Boudný V; Kocák I; Lauerová L; Kovarík J
Folia Biol (Praha); 2003; 49(4):142-6. PubMed ID: 12971583
[TBL] [Abstract][Full Text] [Related]
4. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
6. STAT5 contributes to interferon resistance of melanoma cells.
Wellbrock C; Weisser C; Hassel JC; Fischer P; Becker J; Vetter CS; Behrmann I; Kortylewski M; Heinrich PC; Schartl M
Curr Biol; 2005 Sep; 15(18):1629-39. PubMed ID: 16169484
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
Clin Cancer Res; 2003 Jun; 9(6):2166-72. PubMed ID: 12796382
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
Carson WE
Clin Cancer Res; 1998 Sep; 4(9):2219-28. PubMed ID: 9748142
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells.
Manara MC; Serra M; Benini S; Picci P; Scotlandi K
Int J Oncol; 2004 Feb; 24(2):365-72. PubMed ID: 14719113
[TBL] [Abstract][Full Text] [Related]
10. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of phosphorylated STAT-1alpha in the labial salivary glands of patients with Sjögren's syndrome.
Wakamatsu E; Matsumoto I; Yasukochi T; Naito Y; Goto D; Mamura M; Ito S; Tsutsumi A; Sumida T
Arthritis Rheum; 2006 Nov; 54(11):3476-84. PubMed ID: 17075845
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
13. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of primary and regional melanoma].
Dreno B
Rev Prat; 2004 Jun; 54(11):1203-9. PubMed ID: 15496027
[TBL] [Abstract][Full Text] [Related]
15. Mediators of interferon gamma-initiated signaling in bovine luteal cells.
Suter J; Hendry IR; Ndjountche L; Obholz K; Pru JK; Davis JS; Rueda BR
Biol Reprod; 2001 May; 64(5):1481-6. PubMed ID: 11319155
[TBL] [Abstract][Full Text] [Related]
16. Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor.
Wang S; Tyring SK; Townsend CM; Evers BM
Ann Surg Oncol; 1998; 5(7):642-9. PubMed ID: 9831114
[TBL] [Abstract][Full Text] [Related]
17. Genomic DNA affinity chromatography: a technique to isolate interferon-inducible DNA binding factors.
Kumaran J; Fish EN
Methods Mol Med; 2005; 116():57-67. PubMed ID: 16000854
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of potential Stat3-regulated genes in human breast cancer.
Hsieh FC; Cheng G; Lin J
Biochem Biophys Res Commun; 2005 Sep; 335(2):292-9. PubMed ID: 16081048
[TBL] [Abstract][Full Text] [Related]
19. Defective IFNα/γ-induced STAT3 protein activation in human malignant melanoma cells.
Boudny V; Adamkova L; Souckova K; Lauerova L; Krejci E; Fait V
Mol Med Rep; 2008; 1(6):909-15. PubMed ID: 21479505
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.
Humpoliková-Adámková L; Kovařík J; Dušek L; Lauerová L; Boudný V; Fait V; Fojtová M; Krejčí E; Kovařík A
Eur J Cancer; 2009 May; 45(7):1315-1323. PubMed ID: 19232485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
